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Background: Lung cancer has been considered as one of the most important causes of cancer-related mortality
worldwide. To predict lung cancer, researchers identified several molecular markers. However, many underlying markers
of lung cancer remain unclear. One of these markers is Rab GDP dissociation inhibitor beta (GDIβ), which is related to
tumorigenicity, development and invasion. This study was designed to analyze the biological characteristics of Rab
GDIβ and to detect the mRNA and protein expressions of Rab GDIβ in lung cancer cells; this study also aimed to
investigate the functions of this protein in lung cancer.
Method: Using online software from the websites of NCBI, ProtParam and so on, we analyzed the biological
characteristics of Rab GDIβ. RT-PCR was performed to detect gene expressions in A549 and 16HBE cell lines and
immunohistochemistry (IHC) staining was conducted to detect Rab GDIβ protein expression in 57 cases of human
lung cancer tissues and 19 cases of normal lung tissues. The association of protein expression with patient clinical
and pathological characteristics was assessed in each dataset.
Results: Bioinformatic analysis on Rab GDIβ: The mRNA of human Rab GDIβ contains two transcript variants; the
common structural elements of the two proteins are mainly α-helix, random coil, β-turn and extended strand. Three and
four transmembrane domains could be found in the entire polypeptide chain of protein variants 1 and 2, respectively;
both transcript variants are hydrophilic and soluble proteins. The RT-PCR result: The mRNA expression of Rab GDIβ was
down-regulation in A549 cells compared with that in 16HBE cells. The IHC result: The protein expression of Rab GDIβ in
lung cancer cells was significantly lower than that in normal lung tissues (P <0.05) but was not correlated with patients’
age, gender, tumor size, pathological type, differentiation, lymph node metastasis, distant metastasis and TNM stage.
Conclusion: The expression of Rab GDIβ was low in non-small cell lung cancer (NSCLC). Hence, Rab GDIβ may be
a tumor suppressor and could function as an indicator of tumorigenesis in NSCLC; nevertheless, this result should
be further studied.
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Lung cancer has been considered as one of the most
common malignancies and yields the lowest survival rate
among other cancers [1]. Non-small cell lung cancer
(NSCLC) accounts for more than 80% of all lung can-
cers. Mortality related to this malignant disease has in-
creased by 465% during the last 30 years in People’s
Republic of China [2]. Even those NSCLC patients have
received standard treatments, including surgical resec-
tion, traditional chemotherapy, radiation therapy and
molecular targeted therapy, the five-year survival rate of
NSCLC is still lower than 15% [3-5]. It has long been ac-
knowledged that the aggressive nature of lung cancer is
closely related to the activation of oncogenes and the in-
activation of tumor suppressor genes [6-8]. However, nu-
merous molecular alterations are involved in lung cancer
development [9]; cancer initiation, progression and metas-
tasis also remain poorly understood. Thus far, we still lack
markers that can be used in early detection and targeted
therapy. Therefore, novel cancer-specific molecular targets
and signalling pathways should be developed to establish
new therapeutic strategies against this devastating malig-
nancy and to improve patient survival.
In our previous study on mitochondria proteomics, dif-
ferent proteins containing Rab GDP dissociation inhibitor
beta (GDIβ) were screened and identified [10]. Rab GDIβ
is a member of the GDP dissociation inhibitor family that
controls the recycling of Rab GTPases involved in mem-
brane trafficking [11,12]. Rab GTPases, one of the Ras
superfamily members of monomeric GTPases, are small
G proteins. In recent years, a new function of Rab proteins
has been observed in the control of tumor progression.
Evidence [13-19] has further shown that Rab proteins are
necessary to facilitate cancer cell adhesion and migration.
As a Rab protein control factor, Rab GDIβ is also involved
in the development of multiple tumors. Rab GDIβ con-
trols the access of GTPases to regulatory guanine nucleo-
tide exchange factors and GTPase-activating proteins [20];
Rab GDIβ may also function in tumor cell apoptosis [21].
Wang et al. [22] discovered that Rab GDIβ was signifi-
cantly up-regulated in the highly metastatic gallbladder
carcinoma cells GBC-SD18H compared with the poorly
metastatic GBC-SD18L cell line. Proteomic analysis re-
sults have also shown that Rab GDIβ expressions in
gastric cancer [23] and ovarian cancer [24] were aber-
rant compared with those in normal tissues. Therefore,
Rab GDIβ possibly participates in cancer initiation and
progression.
However, whether Rab GDIβ is involved in the develop-
ment of NSCLC is yet to be reported. In the present study,
the biological characteristics of Rab GDIβ were analyzed.
RT-PCR was conducted to detect the mRNA expression
levels of Rab GDIβ in lung adenocarcinoma cell line A549
and normal human bronchial epithelial cell line 16HBE.Immunohistochemistry (IHC) was performed to quantify
the protein expression of Rab GDIβ in lung cancer tissues.
Then the relationship between this expression and clinico-
pathological factors was examined. These studies may
provide important references related to the potential func-
tion of Rab GDIβ in human NSCLC progression.
Methods
Bioinformatics analysis
Biological characteristics, including physicochemical
properties, homology, secondary structure, transmem-
brane domain, functional domain, subcellular localisation,
three-dimensional (3D) structure, phosphorylation sites
and functions of Rab GDIβ, were analyzed using online
software from the websites of NCBI, ProtParam, SOPMA,
TMpred, SMART, ProtScale, SOSUI, PSORT II, Swiss-
MODEL Repository and so on. The gene and protein
interaction networks of Rab GDIβ were established on the
basis of the platform of GeneMANIA and STRING9.0.
Cell culture
Human lung adenocarcinoma cells A549 were obtained
from the central laboratory of Xi’an Jiaotong University
and grown in a complete medium containing RPMI 1640
supplemented with 10% foetal bovine serum and pen/
strep (100 U/ml penicillin and 100 U/ml streptomycin).
The cells were grown at 37°C in an incubator with a hu-
midified atmosphere of 5% CO2 until confluency was
reached. Human normal bronchial epithelial cells 16HBE
were kindly provided by the tumor Cell Library of the
Chinese Academy of Medical Sciences.
Patients and tissue procurement
57 patients with primary lung cancer who underwent
surgical resection at the Department of Thoracic Sur-
gery of the Second Affiliated Hospital of Xi’an Jiaotong
University, between June 2006 and June 2011, without
pre-operative chemotherapy and/or radiation therapy,
were enrolled in this study. 19 cases of normal lung tis-
sues were benign lung lesions or at least 5 cm distant
from the cancer site. The collections of lung cancer were
mainly NSCLC (32 adenocarcinomas, 19 squamous carcin-
omas, 2 adenosquamous carcinoma, 1 carcinoid, 1 small
cell lung cancer (SCLC), 1 pulmonary metastatic tumor
from the oesophagus and 1 pulmonary metastatic tumor
from the cervix). Patients’ characteristics, such as gender,
age, pathological pattern, lymph node invasion and Union
for International Cancer Control (UICC) stage, are sum-
marised in Table 1. The tissue procurement protocol used
in this study was approved by the Human Research Com-
mittee of Xi’an Jiaotong University, and a written informed
consent was obtained from each patient. All of the fresh
tumor specimens and normal lung tissues were collected
Table 1 Correlation between clinicopathological characteristics and Rab GDIβ expression
Variables Patients [n(%)] Positive Negative Positive rate (%) P
Age
≥65 31 8 23 25.8 0.740
<65 20 6 14 30.0
Gender
Male 27 7 20 25.9 0.791
Female 24 7 17 29.2
Tumor size (cm)
≥3.5 26 7 19 26.9 0.920
<3.5 25 7 18 28.0
Histology
Adenocarcinoma 32 9 23 28.1 0.889
Squamous carcinomas carcinomas 19 5 14 26.3
Differentiation
G1-G2 30 8 22 26.7 0.888
G3 21 6 15 28.6
Lymph node metastasis
Node-positive 29 7 22 24.1 0.543
Node-negative 22 7 15 31.8
Distant metastasis
Yes 4 2 2 50.0 0.300※
No 47 12 35 25.5
TNM stage
I ~ II 24 7 17 29.2 0.796
III ~ IV 27 7 20 25.9
※Fisher's exact test was used.
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stored at −80°C until analysis.
Primary reagent
RPMI 1640 and foetal bovine serum were purchased from
Hyclone (USA). RNAfast200 and RevertAid™ first-strand
cDNA synthesis kit were separately obtained from Feijie
Biotechnology Company (Shanghai, China) and Fermentas
(USA). Rabbit polyclonal antibody against Rab GDIβ was
purchased from ProteinTech (USA).
RT-PCR
Total RNA was extracted from cultured cells with
RNAfast200 according to the manufacturer’s instruc-
tions. A total of 1 μg of RNA was used for reverse tran-
scription; cDNA was generated and used as a template
for RT-PCR analysis. RT-PCR was then performed
using the RevertAid™ first-strand cDNA synthesis kit.
PCR conditions for all of the reactions were as follows:
Rab GDIβ, 94°C for 3 min, 94°C for 30 s, 50°C for 30 s
and 72°C for 1 min (30 cycles) and 72°C for 5 min; and
β-actin, 94°C for 3 min, 94°C for 30 s, 58°C for 30 s and72°C for 1 min (30 cycles) and 72°C for 5 min. Gel im-
ages were collected by applying conventional electro-
phoresis on the PCR product. The expression levels of
Rab GDIβ in A549 and 16HBE cell lines were evaluated
using ImageJ 1.44 software and under the reference of
β-actin. Each experiment above-mentioned was per-
formed in triplicate.
Immunohistochemistry
IHC staining was conducted according to standard
streptavidin-perosidase (SP) methods. In brief, the tis-
sue specimens were fixed in neutral buffered formalin
and then embedded in paraffin wax. Tissue sections
(thickness = 4 μm) were dewaxed, rehydrated, subjected
to heat-induced antigen retrieval and blocked with nor-
mal goat serum for 15 min. The slides were incubated
with rabbit polyclonal antibody against Rab GDIβ at 4°C
overnight, rinsed with phosphate buffered saline (PBS) and
incubated with horseradish peroxidase-labelled secondary
antibody. Rab GDIβ localisation was revealed using 3,3ʹ-
diaminobenzidine (DAB) as a chromogen. Negative control
experiment was performed by replacing the primary antibody
Figure 1 Analysis of the secondary structure of Rab GDIβ (A, protein variant 1; B, protein variant 2).
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Figure 2 Prediction of the 3D structure of Rab GDIβ (A, protein
variant 1; B, protein variant 2).
Figure 3 Network diagram of Rab GDIβ gene interaction.
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assessed using a semi-quantitative staining index method
[25]. The percentage of positive cells was assessed quantita-
tively and scored as follows: 0, <5% of the total counted
cells were stained; 1, 5% to 24% of the total counted cells
were stained; 2, 25% to 50% of the total counted cells were
stained; and 3, >50% of the total counted cells were stained.
Intensity was graded as follows: 0, no signal; 1, weak; 2,
moderate; and 3, strong staining. A staining index ranging
from 0 to 6 was generated by multiplying the percentage
of positive cells and staining intensity of each sample.
The total staining score was also graded as negative (–,
score 0), weak (+, score 1 to 2), moderate (++, score 3 to
4), or strong (+++, score 5 to 6). “–” was defined as
negative expression, and “+, ++, +++” were defined as
positive. All of the slides were examined and scored inde-
pendently by two pathologists who were blinded from the
patient data.
Statistical analysis
The associations between IHC staining and clinicopath-
ological factors were examined by χ2 test and Fisher’s
exact test. Statistical analysis was performed using the
Statistical Package for the Social Sciences (SPSS) 19.0 soft-
ware, and P <0.05 was considered statistically significant.
Results
Biological characteristics of Rab GDIβ
Rab GDIβ gene is located at chromosome 10p15 and
measures a total length of 48327 bp. The mRNA of hu-
man Rab GDIβ exhibits two transcript variants. Tran-
script variant 1 is 2441 bp long; the initiation codon of
the gene is ATG and the termination codon is TAA. The
open reading frame of this variant ranges from 292 bp
to 1629 bp. Furthermore, transcript variant 1 contains
11 exons and 10 introns. Transcript variant 2 is 2306 bp
long. The initiation codon of the gene is ATG and the
termination codon is TAA. The open reading frame of
this variant ranges from 292 bp to 1494 bp. Transcript
variant 2 also contains 10 exons and 9 introns. A high
degree of genetic homology is observed in human, gib-
bon, wren and macaque. For instance, transcript variant
1 is composed of 445 amino acids with a relative mo-
lecular mass of approximately 50663.2D; the theoretical
isoelectric point and the half-life of this variant are 6.10
and 30 h, respectively. Transcript variant 2 is composed
of 400 amino acids with a relative molecular mass of ap-
proximately 45619.4D; the theoretical isoelectric point
and the half-life of this variant are 5.91 and 30 h. The
common structural elements of these two proteins are
mainly α-helix, random coil, β-turn and extended strand
(Figure 1). Furthermore, three and four transmembrane
domains can be found in the entire polypeptide chain of
protein variants 1 and 2, respectively. Both variants arehydrophilic and soluble proteins. One and two GDI ac-
tivity regions are also found in protein variants 1 and 2,
respectively. The subcellular localisation of protein vari-
ant 1 was analysed and revealed that this protein may be
present in the following organelles: 39.1% in the cyto-
plasm; 17.4% in the mitochondria; 17.4% in the nucleus;
13.0% in the endoplasmic reticulum; 4.3% in the secretory
vesicles; 4.3% in the Golgi apparatus; and 4.3% in the per-
oxisome. Likewise, the subcellular localisation of protein
variant 2 was analysed and revealed that this protein may
be present in the following organelles: 39.1% in the cyto-
plasm; 21.7% in the nucleus; 17.4% in the mitochondria;
8.7% in the endoplasmic reticulum; 4.3% in the secretory
vesicles; 4.3% in the Golgi apparatus; and 4.3% in the
peroxisome. The 3D structure of Rab GDIβ protein was
predicted using Swiss-MODEL Repository software
(Figure 2). The network diagram of Rab GDIβ gene
interaction was obtained using GeneMANIA software
(Figure 3). The network diagram of Rab GDIβ protein
interaction was constructed using STRING9.0 software
and by imposing restrictions on the search conditions
within 20 genes (Figure 4).
Figure 4 Network diagram of Rab GDIβ protein interaction.
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The electrophoresis results of the mRNA level of Rab
GDIβ in A549 and 16HBE cell lines are shown in
Figure 5. In particular, the mRNA level of Rab GDIβ in
A549 was down-regulated. Using ImageJ 1.44 software
and β-actin as a reference, we found that the relative ex-
pression level of Rab GDIβ in A549 was 0.25 ± 0.07.
Protein expression of Rab GDIβ in tissue specimens
Human lung cancer and normal lung tissue specimens
were immunohistochemically stained. Our results showed
that Rab GDIβ was expressed in the cell membrane and
the cytoplasm, as indicated by brown granules (Figure 6).
The IHC results also showed that 12 of 19 (63.2%) normalFigure 5 Electrophoresis of the Rab GDIβ gene PCR product in A549lung samples were positively stained. Among the 57 lung
cancer cases, only 18 showed positive expression, and the
positive rate was only 31.6%. The protein expression
level of Rab GDIβ in adenocarcinoma was uniformly
and significantly decreased (P = 0.014) compared with
normal samples. Similarly, χ2 test showed that the P-
value between squamous carcinomas and normal tis-
sues is 0.022, meaning that the expressions in squamous
carcinomas and normal tissues were also significantly dif-
ferent. Thus, Rab GDIβ expression was either absent or
decreased in NSCLC.
Associations between IHC staining and clinicopathological
factors
The Rab GDIβ protein expression in NSCLC tissues
was not correlated with the patients’ clinicopathological
characteristics, such as age, gender, tumor size, patho-
logical type, differentiation, lymph node metastasis, dis-
tant metastasis and tumor node metastasis (TNM)
stage (Table 1). Adenosquamous carcinoma, carcinoid,
SCLC and metastatic carcinoma were removed during
the analysis because the included cases were very few.
Discussion
Bioinformatics is a new discipline that combines computer
techniques and applied mathematics; bioinformatics is also
a major core area of life science and natural science. In the
current study, bioinformatics was applied to analyze the
biological characteristics of Rab GDIβ. Our result revealed
high homology in humans and other species, suggesting
that Rab GDIβ is conservative and implicated in in vivo
processes. Rab GDIβ is primarily located in the cytoplasm
and the organelles of membrane structures; this resultand 16HBE cell lines (M: marker).
Figure 6 Expressions of Rab GDIβ in normal lung tissue (A, IHC, 200×), adenocarcinoma (B, IHC, 100×) and squamous carcinomas
(C, IHC, 200×).
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vesicle transport. Gene and proteins interacting with Rab
GDIβ are mainly family members of small G proteins. We
could take these data to analyze the biological process and
signal transduction pathways which Rab GDIβ may partici-
pate in. Thus, bioinformatics provided relevant information
to elucidate the structure and function of Rab GDIβ.
Rab GDIβ translocates prenylated Rab proteins from
the cytosol to the membrane to form budding transport
vesicles. Rab GDIβ also assists the subsequent retrieval
of Rab proteins [26,27]; some of these proteins are
tumorigenic or tumor suppressive [28]. Although the
functions of Rab proteins in cancer progression have
been studied intensively, information on Rab GDIβ ac-
tion in this regard remains limited. Thus far, few ex-
pression studies have suggested that Rab GDIβ can
activate or inhibit tumor progression. Sun et al. [29]
conducted IHC and western blot analyzes, confirming
that the increased level of GDIβ is associated with pan-
creatic carcinoma. In another study, proteomic analysis
result has shown that GDIβ is identified as an up-
regulated protein with the effect of retinoic acids on
the human breast cancer cell line MCF-7 [30]. By con-
trast, the expression levels of GDIβ in SKpac cells and
chemo-resistant human ovarian cancer tissues are
down-regulated [24].
In the current study, the mRNA concentrations of Rab
GDIβ of lung adenocarcinoma cells and normal human
bronchial epithelial cells were quantified by RT-PCR. This
study is the first to report that the expression level of Rab
GDIβ in lung adenocarcinoma cells was significantly lower
than that in normal cells. Considering that mRNA expres-
sion may not accurately reflect protein level, we detected
protein levels by IHC to verify this conclusion. The results
showed that the protein level of Rab GDIβ varied with the
corresponding mRNA level of Rab GDIβ in NSCLC and
normal tissues; however, the protein level was not associ-
ated with patients’ age, gender, tumor size, pathological
type, differentiation, lymph node metastasis, distant me-
tastasis and TNM stage. These findings suggested that the
expression of Rab GDIβ in NSCLC was low, and this pro-
tein may be a candidate biomarker that could be used to
diagnose NSCLC in early stages. This protein could alsobe used to provide new insights into the pathological
mechanisms of tumor formation and development.
In a previous study, Rab GDIβ is considered as a gene
that promotes differentiation and apoptosis but inhibits
proliferation in various tumors. The current study sug-
gested that Rab GDIβ was associated with human
NSCLC. Rab GDIβ could be a potentially valuable prog-
nostic indicator in patients with NSCLC. This informa-
tion may also be used as reference by clinicians when
they provide individualised therapy with optimal benefits
for patients with NSCLC.
Conclusion
In summary, our data showed for the first time that the
expression of Rab GDIβ decreased in human NSCLC.
Rab GDIβ level was not correlated with patients’ age,
gender, tumor size, pathological type, differentiation,
lymph node metastasis, distant metastasis and TNM
stage. Rab GDIβ may be used as a novel marker in
early-onset human NSCLC. However, the current study
is only a preliminary report, and the number of samples
in this research is limited; thus, further experiments
should be conducted to confirm our conclusion. We
recommend that a larger sample size should be used in
future studies, and a cell excessive expression vector
should be established to investigate the specific func-
tions of Rab GDIβ in NSCLC.
Abbreviation
Rab GDIβ: Rab GDP dissociation inhibitor beta; NSCLC: non-small cell lung
cancer; IHC: immunohistochemistry; 3D: Three-dimensional; SCLC: Small cell
lung cancer; UICC: Union for International Cancer Control; SP: Streptavidin-
perosidase; PBS: Phosphate buffered saline; TNM: Tumor node metastasis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SYY and ZJM conceived and designed the study. CLG, MHJ and WL reviewed
related literature and performed bioinformatics and statistical analyzes. YPZ, NF
and YJZ conducted cell culture, RT-PCR and immunohistochemical studies. WL
and XM extracted data and analyzed the relationship between immunostaining
and clinicopathological factors. ZJM and MHJ drafted the manuscript. SYY
reviewed and edited the manuscript. All of the authors have read and approved
the final manuscript.
Acknowledgements
We thanks three anonymous reviewers for their insightful suggestions.
Ming et al. Diagnostic Pathology 2014, 19:201 Page 8 of 8
http://www.diagnosticpathology.org/content/19/1/201Author details
1Department of Respiratory Medicine, the Second Affiliated Hospital of Xi’an
Jiaotong University, Xi’an 710004, China. 2Department of Respiratory
Medicine, People’s Hospital of Tongchuan City, Tongchuan 727000, China.
Received: 6 March 2014 Accepted: 8 October 2014References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61(2):69–90.
2. Wen C, Dehnel T: People’s Republic of China wrestles with lung cancer.
Lancet Oncol 2011, 12(1):15.
3. Chen G, Gharib TG, Wang H, Huang CC, Kuick R, Thomas DG, Shedden KA,
Misek DE, Taylor JM, Giordano TJ, Kardia SL, Iannettoni MD, Yee J, Hogg PJ,
Orringer MB, Hanash SM, Beer DG: Protein profiles associated with survival
in lung adenocarcinoma. Proc Natl Acad Sci U S A 2003,
100(23):13537–13542.
4. Molina JR, Adjei AA, Jett JR: Advances in chemotherapy of non-small cell
lung cancer. Chest 2006, 130(4):1211–1219.
5. Husain H, Rudin CM: ALK-targeted therapy for lung cancer: ready for
prime time. Oncology 2011, 25(7):597–601.
6. Rom WN, Hay JG, Lee TC, Jiang Y, Tchou-Wong KM: Molecular and genetic
aspects of lung cancer. Am J Respir Crit Care Med 2000,
161(4 Pt 1):1355–1367.
7. Geradts J, Fong KM, Zimmerman PV, Maynard R, Minna JD: Correlation of
abnormal RB, p16ink4a, and p53 expression with 3p loss of
heterozygosity, other genetic abnormalities, and clinical features in 103
primary non-small cell lung cancers. Clin Cancer Res 1999, 5(4):791–800.
8. Sozzi G, Carney D: Molecular biology of lung cancer. Curr Opin Pulm Med
1998, 4(4):207–212.
9. Motadi LR, Misso NL, Dlamini Z, Bhoola KD: Molecular genetics and
mechanisms of apoptosis in carcinomas of the lung and pleura:
therapeutic targets. Int Immunopharmacol 2007, 7(14):1934–1947.
10. Zhang W, Li YT, Yang SY, Li W, Ming ZJ, Zhang YP, Hou YL, Niu ZQ, Rong
BX, Zhang XD, Liu XL: Differential mitochondrial proteome analysis of
human lung adenocarcinoma and normal bronchial epithelium cell lines
using quantitative mass spectrometry. Thoracic Cancer 2013,
10(7):374–379.
11. Sedlacek Z, Konecki DS, Korn B, Klauck SM, Poustka A: Evolutionary
conservation and genomic organization of XAP-4, an Xq28 located gene
coding for a human rab GDP- dissociation inhibitor (GDI).
Mamm Genome 1994, 5(10):633–639.
12. Wu SK, Zeng K, Wilson IA, Balch WE: Structural insights into the function
of the Rab GDI superfamily. Trends Biochem Sci 1996, 21(12):472–476.
13. Subramani D, Alahari SK: Integrin-mediated function of Rab GTPases
in/cancer progression. Mol Cancer 2010, 9(1):312.
14. Nam KT, Lee HJ, Smith JJ, Lapierre LA, Kamath VP, Chen X, Aronow BJ,
Yeatman TJ, Bhartur SG, Calhoun BC, Condie B, Manley NR, Beauchamp RD,
Coffey RJ, Goldenring JR: Loss of Rab25 promotes the development of
intestinal neoplasia in mice and is associated with human colorectal
adenocarcinomas. J Clin Invest 2010, 120(3):840–849.
15. Liu SS, Chen XM, Zheng HX, Shi SL, Li Y: Knockdown of Rab5a expression
decreases cancer cell motility and invasion through integrin-mediated
signaling pathway. J Biomed Sci 2011, 18(1):58.
16. Barbarin A, Frade R: Procathepsin L secretion, which triggers tumor
progression, is regulated by Rab4a in human melanoma cells. Biochem J
2011, 437(1):97–107.
17. Yang Q, Jie Z, Cao H, Greenlee AR, Yang C, Zou F, Jiang Y: Low-level
expression of let-7a in gastric cancer and its involvement in
tumorigenesis by targeting RAB40C. Carcinogenesis 2011, 32(5):713–722.
18. Hendrix A, Braems G, Bracke M, Seabra M, Gahl W, De Wever O, Westbroek
W: The secretory small GTPase Rab27B as a marker for breast cancer
progression. Oncotarget 2010, 1(4):304–308.
19. Yang PS, Yin PH, Tseng LM, Yang CH, Hsu CY, Lee MY, Horng CF, Chi CW:
Rab5A is associated with axillary lymph node metastasis in breast cancer
patients. Cancer Sci 2011, 102(12):2172–2178.
20. DerMardirossian C, Bokoch G: GDIs: central regulatory molecules in Rho
GTPase activation. Trends Cell Biol 2005, 2005(15):356–363.21. Kwon K, Park E, Ryu D, Park B: D4-GDI is cleaved by caspase-3 during
daunorubicin- induced apoptosis in HL-60 cells. Exp Mol Med 2002,
34:32–37.
22. Wang JW, Peng SY, Li JT, Wang Y, Zhang ZP, Cheng Y, Cheng DQ, Weng
WH, Wu XS, Fei XZ, Quan ZW, Li JY, Li SG, Liu YB: Identification of
metastasis-associated proteins involved in gallbladder carcinoma
metastasis by proteomic analysis and functional exploration of chloride
intracellular channel 1. Cancer Lett 2009, 281(1):71–81.
23. Bai Z, Ye Y, Liang B, Feng X, Zhang H, Zhang Y, Peng J, Shen D, Cui Z,
Zhang Z, Wang S: Proteomics-based identification of a group of
apoptosis-related proteins and biomarkers in gastric cancer. Int J Oncol
2011, 38(2):375–383.
24. Lee DH, Chung K, Song JA, Kim TH, Kang H, Huh JH, Jung SG, Ko JJ, An HJ:
Proteomic identification of paclitaxel-resistance associated hnRNP A2
and GDI2 proteins in human ovarian cancer cells. J Proteome Res 2010,
9(11):5668–5676.
25. Fromowitz FB, Viola MV, Chao S, Oravez S, Mishriki Y, Finkel G, Grimson R,
Lundy J: Ras p21 expression in the progression of breast cancer.
Hum Pathol 1987, 18(12):1268–1275.
26. Pfeffer SR, Dirac-Svejstrup AB, Soldati T: Rab GDP dissociation inhibitor:
putting rab GTPases in the right place. J Biol Chem 1995,
270(29):17057–17059.
27. Stenmark H, Olkkonen VM: The Rab GTPase family. Genome Biol 2001, 2:5.
REVIEWS3007.
28. Chia W, Tang B: Emerging roles for Rab family GTPases in human cancer.
Biochem Biophys Acta 2009, 1795(2):110–116.
29. Sun ZL, Zhu Y, Wang FQ, Chen R, Peng T, Fan ZN, Xu ZK, Miao Y: Serum
proteomic- based analysis of pancreatic carcinoma for the identification
of potential cancer biomarkers. Biochim Biophys Acta 2007, 774(6):764–771.
30. Kamal AHM, Han BS, Choi JS, Cho K, Kim SY, Kim WK, Lee SC, Bae KH:
Proteomic analysis of the effect of retinoic acids on the human breast
cancer cell line MCF-7. Mol Biol Rep 2014, 41(5):3499–3507.
doi:10.1186/s13000-014-0201-0
Cite this article as: Ming et al.: Bioinformatics analysis of Rab GDP
dissociation inhibitor beta and its expression in non-small cell lung
cancer. Diagnostic Pathology 2014 19:201.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
